The Amyloid Cascade Hypothesis
The American Journal of Pathology · 2025-11 · 195 (11) · 1988-1997
DOI: 10.1016/j.ajpath.2024.10.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The American Journal of Pathology, 2025-11. Verfasst von Rudy J Castellani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: rudolph.castellani@nm.org. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Amyloidosis, Amyloid. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The amyloid cascade hypothesis as the etiological underpinning of Alzheimer disease (AD) is supported by a large body of literature, the most influential of which are genetic studies of the 1980s and 1990s. Other evidence includes the neuropathology of Down syndrome, apparent toxicity of oligomeric amyloid-β (Aβ), interactions with apolipoprotein E, and the analogy of cardiac amyloidosis. However, there is considerable phenotypic heterogeneity among the rare familial AD kindreds, which tempers extrapolation to sporadic AD. Oligomer biology is still in the theoretical realm, with no clinical validation. Apolipoprotein E support for the amyloid cascade and other inferences from the literature are somewhat circular in their logic. Analogy with amyloidoses might also consider secondary amyloidosis, driven by systemic inflammation and treated by treating the underlying etiology. Much of the remaining literature supporting the amyloid cascade is dominated by hypothesis-generating studies. Importantly, we now have a developing evidence base from controlled clinical trials that can potentially inform the issue of Aβ as a cause or driver of disease in sporadic AD. Emerging data provide clear evidence of target engagement. Clinical outcome, however, has been either marginally positive or similar to placebo. Assuming these findings hold, it appears that Aβ neither drives nor mitigates the disease process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Neuropathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: rudolph.castellani@nm.org.
- Division of Neuropathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
- Department of Neuroscience, Developmental and Regenerative Biology, The University of Texas at San Antonio, San Antonio, Texas.
Förderung
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Castellani, R. J., Jamshidi, P., Plascencia-Villa, G., & Perry, G. (2025). The Amyloid Cascade Hypothesis. The American Journal of Pathology, 195(11), 1988-1997. https://doi.org/10.1016/j.ajpath.2024.10.014
Vancouver
Castellani RJ, Jamshidi P, Plascencia-Villa G, Perry G. The Amyloid Cascade Hypothesis. The American Journal of Pathology. 2025;195(11):1988-1997. doi:10.1016/j.ajpath.2024.10.014
BibTeX
@article{Castellani2025,
author = {Castellani, Rudy J and Jamshidi, Pouya and Plascencia-Villa, Germán and Perry, George},
title = {The Amyloid Cascade Hypothesis},
journal = {The American Journal of Pathology},
year = {2025},
volume = {195},
number = {11},
pages = {1988--1997},
doi = {10.1016/j.ajpath.2024.10.014}
}
EUVIMED